Cancer and Leukemia Group B

描述（由申请人提供）：杜克大学医学中心作为癌症和白血病B组（CALGB）的成员，目前正在完成其第四个资助周期。在过去的二十年中，杜克大学一直是患者总收益排名前五的机构之一。当前申请的目标和具体目的是继续保持这种高水平的患者登记，并结合我们的教师在治疗试验和相关科学研究开发中的广泛科学参与。另一个目标是通过提供广泛的癌症临床试验，不仅在杜克大学，而且通过我们的杜克肿瘤网络（DON）在北卡罗来纳州服务不足的社区和美国东南部的研究分支机构，进一步发展我们的临床试验组织。在当前的拨款周期中，杜克大学招收了866名患者，唐顿大学招收了近1900名患者。这种对CALGB活动的高水平临床承诺与杜克大学教师的高水平科学参与相匹配。擅长的领域包括乳腺癌及相关研究、老年癌症、白血病/淋巴瘤、呼吸系统癌症和胸外科。教师招聘扩大了我们在所有这些领域的实力，并为Gl和GU的癌症项目提供了重大增长。杜克大学的教职员工在CALGB生物标志物研究和基因组治疗试验方面做出了重大贡献。为了改善监管和有效利用资源，杜克大学癌症临床试验已重组为癌症中心内的肿瘤现场研究（SBR）实体，其中包括CALGB活动。SBR/ CALGB负责监督杜克大学和整个唐顿大学的疾病和特定地点的临床研究团队，其中包括北卡罗来纳州的10个社区站点，由杜克大学的教职员工和研究护士组成，以及11个研究附属站点。这个组织结构是在过去20年里，在CALGB活动的首席研究员Jeffrey Crawford博士的指导下发展起来的。杜克大学的活动通过与总部设在杜克大学的CALGB生物统计和数据管理中心的密切互动得到进一步加强，该中心在Stephen George博士的指导下，他也是杜克大学综合癌症中心的生物统计主任。在下一个拨款周期中，我们建议利用这些资源进一步增加合作小组临床试验的患者登记，加强我们在小组中的科学参与，并为服务不足的人群扩大临床试验的机会。

DESCRIPTION (provided by applicant): Duke University Medical Center is currently completing its fourth grant cycle as a member of Cancer and Leukemia Group B (CALGB). Over the last two decades, Duke has consistently been one of the top five institutions in overall patient accrual. The goal and specific aims of the current application are to continue this high level of patient enrollment, combined with broad scientific participation by our faculty in the development of treatment trials and correlative science studies. An additional aim is to further develop our clinical trials organization by providing broad access to cancer clinical trials, not only at Duke, but also in underserved communities of North Carolina and research affiliates across the Southeast United States through our Duke Oncology Network (DON). In the current grant cycle, 866 patients were enrolled at Duke and nearly 1900 patients across the DON. This high level of clinical commitment to CALGB activities is matched by a high level of scientific participation by Duke Faculty. Particular areas of strength include Breast Cancer and Correlative Studies, Cancer in the Elderly, Leukemia/Lymphoma and Respiratory Cancer and Thoracic Surgery. Faculty recruitment has expanded our strength in all of these areas, as well as provided major growth in Gl and GU cancer programs. Duke faculty have made substantial contributions in CALGB biomarker based studies and genomic based treatment trials. To improve regulatory oversight and efficient use of resources, Duke cancer clinical trials have been reorganized into an Oncology Site Based Research (SBR) entity within the Cancer Center which includes CALGB activities. The SBR/ CALGB oversees disease and site specific clinical research teams at Duke and throughout DON, which includes 10 community sites in North Carolina, staffed by Duke faculty and research nurses, as well as 11 research affiliate sites. This organizational structure has been developed over the last 20 years under the direction of Dr. Jeffrey Crawford, who serves as the Principal Investigator of CALGB activities. Activities at Duke are further enhanced by the close interaction with the CALGB biostatistics and data management center headquartered at Duke, under the direction of Dr. Stephen George, who is also Director of Biostatistics at the Duke Comprehensive Cancer Center. In the next grant cycle, we propose to utilize these resources to further increase our patient enrollment on cooperative group clinical trials, enhance our scientific participation within the group and expand access to clinical trials for underserved populations.